The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
If you are not happy with the results below please do another search
50 search results for: drugs in development
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened during 2021. And there are many! The accomplishments, opportunities and possibilities the scientific community has brought to bear, providing a way out of the COVID-19 pandemic and hope for the future of meaningful therapies for several challenging diseases, deserve a major shout-out.
The Food and Drug Administration cleared the way for Tonix Pharmaceuticals to begin a Phase II study of the company’s therapeutic candidate, which intends to prevent migraine headaches.
Pfizer said the company’s Covid-19 vaccine, developed with BioNTech, demonstrated 100 percent effectiveness in the 12-15 year age group after four months. In other news, the U.S. Food and Drug Administration said that it could take over 55 years for the regulatory agency to review and release a complete report on the vaccine-related documentation the FDA currently holds in response to a lawsuit filed by scientists demanding to see the complete records.
Gilead Sciences exercised options to three of Arcus Biosciences’ programs, and the two companies also added a research collaboration deal.
Johnson & Johnson expects to file for approval of 14 new drugs by 2025, and projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company’s pharmaceuticals unit on November 18.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Rigel Pharmaceuticals announced a 16 percent reduction of the company’s workforce, most in early research.
As Biogen continues to struggle with the fallout from the controversial approval of the Alzheimer’s drug Aduhelm, the company’s head of research and development will step down at the end of 2021.
Companies have recently posted major developments in the field of heart disease therapy, including the announcement by AstraZeneca and Moderna that their drug candidate for the treatment of patients with heart failure met the Phase IIA EPICCURE trial’s primary endpoint of safety and tolerability.
With $60 million in hand, Recludix Pharma launched with a mission to develop three SH2 domain inhibitor programs targeting STAT3, STAT6, and an undisclosed non-STAT target for cancer and inflammatory disease targets.